文献速递基础与转化研究临床试验与 GCP新药、器械与细胞基因治疗研发

减轻PARP抑制剂治疗期间的T细胞DNA损伤可增强抗肿瘤疗效

Mitigating T cell DNA damage during PARP inhibitor treatment enhances antitumor efficacy.
PubMed 文献 · Sci Transl Med · 2025-05-07

研究发现,PARP抑制剂(PARPi)治疗期间患者T细胞发生DNA损伤,从而降低疗效。在卵巢上皮癌新辅助尼拉帕利单药临床试验的配对治疗前后肿瘤样本中,PARPi导致T细胞DNA损伤、增殖减慢和凋亡增加,体外和小鼠模型验证一致。全基因组CRISPR敲除筛选显示PARP1是PARPi诱导T细胞死亡的主要介导者;T细胞特异性敲除PARP1或突变其结合位点可减少T细胞DNA损伤并提高PARPi疗效。

要点

  • PARPi治疗期间患者T细胞发生DNA损伤、增殖减慢、凋亡增加,从而降低疗效。
  • 全基因组CRISPR筛选显示PARP1是PARPi诱导T细胞死亡的主要介导者。
  • 用胞嘧啶碱基编辑改造的PARPi耐受CAR-T细胞在异种移植模型中抗肿瘤疗效优于亲本CAR-T细胞。

核心结论

  • PARPi治疗期间T细胞DNA损伤会降低疗效,减轻这种损伤可提高PARPi单药或联合免疫检查点抑制的疗效。

研究设计与样本

  • 基于卵巢上皮癌患者新辅助尼拉帕利单药临床试验的配对治疗前后肿瘤样本,并在体外和小鼠模型中验证。
  • 在原代人类T细胞中进行全基因组CRISPR敲除筛选,并在转基因小鼠中进行T细胞特异性PARP1缺失或Parp1结合位点突变实验。
  • 用胞嘧啶碱基编辑构建PARPi耐受CAR-T细胞,并在异种移植模型中与亲本CAR-T细胞比较。

主要发现

  • PARPi导致患者T细胞DNA损伤、增殖减慢、凋亡增加,体外和小鼠模型验证结果一致。
  • 全基因组CRISPR敲除筛选确定PARP1是PARPi诱导T细胞死亡的主要介导者。
  • T细胞特异性缺失PARP1或突变Parp1结合位点可减少PARPi治疗期间T细胞DNA损伤,并提高PARPi单药或联合免疫检查点抑制的疗效。
  • 胞嘧啶碱基编辑的PARPi耐受CAR-T细胞减少PARPi诱导的PARP1 trapping和DNA损伤,在异种移植模型中抗肿瘤疗效优于亲本CAR-T细胞。

临床怎么用

  • 作者认为,本研究提示PARPi诱导的T细胞DNA损伤与疗效相关,并提示可改善PARPi单药或联合免疫治疗疗效的机会。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Poly(ADP-ribose) polymerase inhibitors (PARPis) are a class of agents targeting DNA damage repair that have become standard therapy for epithelial ovarian cancer (EOC) and multiple other solid tumors. In addition to targeting DNA damage repair, PARPis actively modulate antitumor immune responses, with efficacy being partially dependent on T cell activity. Here, we found that patient T cells sustain DNA damage during PARPi treatment, which reduces treatment efficacy. Leveraging paired pre- and posttreatment tumor samples from a clinical trial of patients with EOC treated with neoadjuvant niraparib as monotherapy, we showed that the PARPi caused DNA damage, slowed proliferation, and increased apoptosis in T cells, which we validated both in vitro and in mouse models. A genome-wide CRISPR (clustered regularly interspaced short palindromic repeats) knockout screen in primary human T cells identified PARP1 as the principal mediator of PARPi-induced T cell death. T cell-specific deletion of PARP1 or mutating Parp1 at its binding sites in transgenic mice led to reduced T cell DNA damage during PARPi treatment, resulting in improved efficacy of PARPis, alone or in combination with immune checkpoint inhibition. We then engineered PARPi-tolerant CAR T cells using cytosine base editing, which decreased PARPi-induced PARP1 trapping and led to reduced PARPi-induced DNA damage, resulting in superior antitumor efficacy in xenograft models compared with parental CAR T cells. This study highlights the relevance of PARPi-induced DNA damage to T cells and suggests opportunities to improve the efficacy of PARPis as monotherapy or in combination with immunotherapy.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Liu J, Jiao X, Mu W, et al. Mitigating T cell DNA damage during PARP inhibitor treatment enhances antitumor efficacy. Sci Transl Med. 2025. PMID: 40333991. doi:10.1126/scitranslmed.adr5861

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。